Company news: Emyria; MedReleaf by Martin Lane March 11, 2024March 11, 2024 Emyria has cited recent media coverage as a possible explanation for a near-30% increase in its […]
Company news: Zelira; ECS Botanics; LGP; Ecofibre; Neurotech; Elixinol; Emyria by Steve Jones and Martin Lane February 28, 2024February 29, 2024
Emyria S3 CBD trial ‘on hold’ as firm stresses need to focus on revenue by Steve Jones February 7, 2024February 7, 2024
Quarterly results: Avecho; Melodiol; Bioxyne/BLS; Emyria; Ecofibre; Zelira; Elixinol; AusCann; Botanix by Steve Jones and Martin Lane January 31, 2024February 1, 2024
Company news: Clever Leaves; Cronos/Vitura; InhaleRX; Emyria; CannMart/Aura Therapeutics; Cann Group; Greenfern Industries; LGP/Reset Mind Sciences by Steve Jones and Martin Lane January 16, 2024January 17, 2024
Company news: Emyria; Wellnex Life; Neurotech International; Melodiol Global Health by Martin Lane November 14, 2023November 14, 2023
Quarterly results: Elixinol; Emyria; Ecofibre; LGP; Bioxyne/BLS; Epsilon; Melodiol; MGC Pharma; AusCann; Neurotech; Wellnex Life; InhaleRx; Cannasouth by Steve Jones and Martin Lane November 1, 2023November 6, 2023
Company news: Setek Therapeutics; Emyria; Melodiol Global Health by Martin Lane October 9, 2023October 12, 2023
Financial results: Bioxyne/BLS; Emyria; Ecofibre; Zelira Therapeutics by Martin Lane October 3, 2023October 3, 2023